A rapid automated method for measuring glycated haemoglobin on the Beckman eX7 analyser S Palfrey and M Labib The measurement of glycated haemoglobin has become an essential test in the monitoring of longterm glycaemic control in diabetic patients.' The availability of results at the time of consultation is important.v' highlighting the need for rapid methods of determination. Currently, most methods employ chromatographic techniques which are relatively slow. Recently, a novel homogeneous immunoassay for HbAlc has been introduced (Tina-Quant HbAlc, Boehringer Mannheim, Tutzing, Germany)." This assay enables the determination of up to 250 glycated haemoglobin tests within one hour on BM/ Hitachi 704 or 717 analysers. We have adapted this method on the Beckman CX7 analyser and we have evaluated its performance in comparison to that of high-performance liquid chromatography (HPLC) on the Shimadzu analyser.
METHODS

Principle
The assay is based on the immunoturbidimetric determination of HbAlc. Glycated haemoglobin (HbAlc) reacts with anti-HbAlc antibody to give a soluble immunocomplex. Polyhaptens then bind to excess antibodies and the resulting agglutinated complexes are measured turbidimetrically. Total haemoglobin is measured simultaneously by photometry at 540 nm and the amount of HbAlc relative to the amount of total haemoglobin is calculated. All Hb variants which are glycated at the N-terminal end of the {3 chain and have identical antibody-recognized regions to that of HbAlc are measured by the assay. This allows the monitoring of diabetics with sickle-cell anaemia, {3-thalassaemia and other haemoglobinopathies (glycated HbE, HbC, HbD, etc.), The antibody Correspondence: Mr S Palfrey. used in the kit does not recognize HbF, but since HbF is not glycated, this is not a disadvantage. Neither acetylated nor carbamylated Hb are detected by this method.
Procedure
Prior to determination, blood specimens [ethylenediaminetetra-acetic acid (EDTA) or fluoride/ oxalate1were mixed with the haemolysing reagent (5 p.Lblood in 500 p.Lreagent). The haemolysates were assayed directly on the Beckman CX7 analyser and no pretreatment was necessary for the elimination of labile HbAI c. The assay is calibrated via a non-linear calibration curve composed of five standards which give an analytical range of o to 2· 5 g/dL. The standards are provided as lyophilised haemolysates and are used after reconstitution without further treatment.
RESULTS
User-defined chemistry print-outs for HbAlc and haemoglobin determination on the Beckman CX7 are shown in Table I . The first result was produced after 20 min and thereafter a result was produced every 32 s at a rate of 112 results per hour. The kit provided sufficient reagent for 360 determinations. The percentage HbAlc was calculated directly using the CX7 on line calculation facilities.
Type of specimen
The Boehringer Mannheim method recommends the use of either EDTA-or heparin-preserved whole blood. As we currently routinely measure HbAlc on fluoride/oxalate preserved specimens, a comparison of paired EDTA and fluoride/ oxalate preserved specimens collected from 20 diabetic patients was made. This showed no significant difference in results (P=0·33).
Stability of standards and reagents
The standards were divided into aliquots (100 p.L) and frozen for storage. Both HbAlc and 
Imprecision
The imprecision of the assay was measured using fluoride/oxalate preserved human blood samples (intra-assay) or control materials (inter-assay). The intra-assay coefficient of variation (CV) was 3·30/0 (n= 20) at HbAlc level of 5'9%,3'4% (n =20) at HbAlc of9'6% and 3'7% (n = 27) at HbAlc of 17.2%. The inter-assay CV was 5· 2% (n = 31) at HbAlc of4'3% and 3·9% (n=3l) at HbAlc of 9·7%.
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Comparison between immunoturbidimetic assay and HPLC One hundred and twenty-six specimens collected from patients attending the diabetic clinic were analysed by both methods (Immunoturbidimetric on Beckman CX7 and HPLC on a Shimadzu system). There was a high degree of correlation between the two methods:
Tina-QuantHbAlc = -1,943 + 1·155 HPLC (r=0'98)
Assessment for use in the diabetic clinic In our hospital, patients attending the diabetic clinic (morning clinic) are asked to attend the pathology department between 0830 h and 1030 h to provide a urine specimen for urinalysis and a blood specimen for glucose concentration. Results are provided to the attending doctor within half an hour, whereas HbAlc results are provided the next day. We have evaluated the simultaneous measurement of HbAlc and plasma glucose on the Beckman eX7 during the diabetic clinic. Between 0830 hand 1030 h specimens were received in the laboratory in small batches (one to seven specimens). Five ILL of blood were mixed with 500 ILL of haemolysing reagent and loaded onto the eX7 for the measurement of total haemoglobin and HbAlc. Specimens were then centrifuged and plasma was assayed for glucose. The first plasma glucose result was available after 7 min and the corresponding HbAlc result after 20 min. However, after this initial delay of 13 min, HbAlc results were available at the same rate as the glucose results.
CONCLUSION
Our evaluation shows that this new immunoturbidimetric assay for HbAlc performs well on the Beckman eX7 analyser. The method is simple with only a single dilution required prior to automated analysis. The method shows good precision and the reagents are stable for at least 3 weeks. The method enables the determination of up to 112 HbAlc results per hour (360 determinations per kit). The cost per test is £1·40 (list price) which is comparable to the cost of most chromatographic methods.
The main advantage, however, over existing chromatographic methods is the capacity of analysing a large number of specimens in a short period of time, thus providing HbAlc results at the time of consultation.
